How the PharmEasy Business Model Links an App, Labs and Chemists

PharmEasy's parent earns from medicines, lab tests and supply to chemists.

How the PharmEasy Business Model Links an App, Labs and Chemists

Key Takeaways

  • FY26 revenue from operations rose 12.7% to ₹6,618.5 crore.
  • The FY26 net loss narrowed to ₹520 crore from ₹1,572 crore in FY25.
  • Product sales brought in ₹5,670 crore, or 85.7% of FY26 revenue.
  • Thyrocare's FY26 revenue rose 21% to ₹829.04 crore.
Table of Contents 12 sections
  1. PharmEasy at a glance
  2. What PharmEasy does
  3. How PharmEasy makes money
  4. Thyrocare, the diagnostics arm
  5. PharmEasy's Business Model Canvas
  6. Is PharmEasy profitable?
  7. The latest quarter
  8. PharmEasy's journey so far
  9. Who PharmEasy competes with
  10. Challenges PharmEasy faces
  11. Conclusion on the PharmEasy business model
  12. FAQs

The PharmEasy business model rests on three businesses run by its parent, API Holdings: the PharmEasy app that sells medicines and health products to households, a B2B arm that supplies medicines to chemists and hospitals, and Thyrocare, a listed diagnostics company that runs lab tests. Most of the money comes from selling products, and a smaller share comes from services such as diagnostics.

In FY26 (the year to March 2026), API Holdings earned ₹6,618.5 crore in revenue from operations, up 12.7%. Its net loss was ₹520 crore, against ₹1,572 crore in FY25.

PharmEasy at a glance

PharmEasy business model at a glance, founders, revenue, loss, valuation and listing status
DetailPharmEasy
What it doesOnline pharmacy, lab tests through Thyrocare, and medicine supply to chemists and hospitals
Parent companyAPI Holdings, Mumbai
Founded2015
Co-foundersSiddharth Shah, Dharmil Sheth, Dhaval Shah, Hardik Dedhia and Harsh Parekh
Revenue (FY26)₹6,618.5 crore revenue from operations, up 12.7%
Net loss (FY26)₹520 crore, down from ₹1,572 crore in FY25
Diagnostics armThyrocare, 51.02% held by the group after an August 2026 sale
ValuationPeak of $5.6 billion in October 2021; a 2023 rights issue was priced about 90% lower
Listing statusUnlisted; IPO papers filed in 2021 were withdrawn in 2022

What PharmEasy does

How the PharmEasy business model works, from an order on the app to lab tests and supply to chemists

On the PharmEasy app and website, customers order prescription medicines, over-the-counter and wellness products, and book diagnostic tests. Medicines are delivered to the home, and lab test samples are collected and processed.

Behind the app sit two other businesses. The B2B arm, made up of Ascent and Aknamed, sells medicines to chemists and hospitals. Thyrocare runs a network of diagnostic labs that receive samples from its franchisees, partners and the PharmEasy app.

PharmEasy business model, the PharmEasy website with medicine search, lab tests and doctor consults
The PharmEasy website, with medicine search, prescription upload and lab test booking.

How PharmEasy makes money

The PharmEasy revenue model has two main parts. In FY26, the sale of products brought in ₹5,670 crore, or 85.7% of revenue from operations. These are medicines and health products sold through the app and to chemists and hospitals. Services brought in ₹941.3 crore, or 14.2%, and include diagnostics and other services.

The group sells medicines and health products to households through the app and to chemists and hospitals through the B2B arm.

The app also lets customers book lab tests alongside a medicine order, which links the consumer business to Thyrocare's labs.

PharmEasy business model revenue by type in FY26, sale of products and services
API Holdings revenue from operations by type, FY26.

Seen by business, the B2B supply arm is the largest. The PharmEasy consumer app earned ₹1,334.5 crore in FY26, and Thyrocare earned ₹829.04 crore.

Thyrocare, the diagnostics arm

API Holdings agreed to buy 66.1% of Thyrocare for ₹4,546 crore in June 2021. Thyrocare earns from blood and other tests, much of it through franchisees who collect samples. Its FY26 revenue rose 21% to ₹829.04 crore from ₹687.35 crore. In April to June 2026, it earned ₹240 crore and ran 55.2 million tests.

In August 2026, the group sold 9.90% of Thyrocare in market trades. Its stake went from 60.92% to 51.02%, so Thyrocare is still a subsidiary. API Holdings used the money from the sale, along with internal accruals, to repay ₹1,050 crore of term debt.

Thyrocare works largely through franchisees, who collect blood samples and send them to its labs for testing. The PharmEasy app adds another channel: a lab test booked on the app is collected at home and processed by the same network.

PharmEasy business model, Thyrocare revenue from FY25 to FY26 and the group stake
Thyrocare revenue and the group stake.

PharmEasy's Business Model Canvas

PharmEasy Business Model Canvas with customers, value, channels, revenue streams, resources, partners and costs
The nine building blocks of the PharmEasy business model.

Is PharmEasy profitable?

No. API Holdings made a net loss of ₹520 crore in FY26, down 67% from ₹1,572 crore in FY25, while revenue from operations rose from ₹5,872 crore to ₹6,618.5 crore. Revenue was ₹5,664 crore in FY24.

PharmEasy business model, revenue from operations and net loss in FY25 and FY26
Revenue and net loss, FY25 and FY26.
PharmEasy business model, revenue from operations from FY24 to FY26
Revenue from operations, FY24 to FY26.

Within the group, the PharmEasy consumer app still ran at an EBITDA loss in FY26.

The latest quarter

In April to June 2026 (Q1 FY27), group revenue rose 10% to ₹1,754 crore, with EBITDA of ₹39.3 crore. The B2B business earned ₹1,005.6 crore. The PharmEasy app earned ₹348 crore, with an EBITDA loss of ₹17 crore.

PharmEasy business model in Q1 FY27, group revenue, EBITDA, app revenue and Thyrocare tests
Key figures for April to June 2026.

PharmEasy's journey so far

PharmEasy business model timeline from its 2015 founding to the 2026 Thyrocare stake sale
Key moments for PharmEasy and API Holdings.
WhenWhat happened
2015PharmEasy is founded in Mumbai
June 2021API Holdings agrees to buy 66.1% of Thyrocare for ₹4,546 crore
October 2021A pre-IPO round of about $350 million values it at $5.6 billion
November 2021Files IPO papers for a ₹6,250 crore issue, later withdrawn in 2022
2023Raises money in a rights issue at about a 90% lower valuation; the round was led by Ranjan Pai's family office
August 2025Siddharth Shah steps down as CEO and Thyrocare's Rahul Guha takes over
September 2025Raises ₹1,700 crore through debentures, pledging about 61% of Thyrocare
August 2026Sells 9.90% of Thyrocare and repays ₹1,050 crore of term debt

Who PharmEasy competes with

PharmEasy business model competitors, Tata 1mg, Apollo 24|7, Netmeds, Dr Lal PathLabs and Metropolis

In online medicines, PharmEasy competes with Tata 1mg, Apollo 24|7 and Netmeds. In diagnostics, Thyrocare competes with lab chains such as Dr Lal PathLabs and Metropolis.

Challenges PharmEasy faces

PharmEasy business model challenges, losses, the consumer app, valuation and listing status

The group was still loss-making in FY26, and the consumer app ran at an EBITDA loss. Its 2023 rights issue was priced about 90% below the 2021 peak valuation of $5.6 billion. API Holdings remains unlisted after withdrawing its IPO papers in 2022.

Conclusion on the PharmEasy business model

The PharmEasy business model in short

The PharmEasy business model combines an online pharmacy, a B2B medicine supply arm and the Thyrocare diagnostics chain under API Holdings. Customers order through the app or website, chemists and hospitals buy through the B2B arm, and Thyrocare's labs process tests from franchisees and the app. Most revenue comes from product sales, with diagnostics and other services making up the rest.

In FY26 the group earned ₹6,618.5 crore in revenue from operations and made a net loss of ₹520 crore.

More from IncBusiness

Join Us Add as preferred source
Share

Frequently Asked Questions

What is the PharmEasy business model?

PharmEasy's parent API Holdings runs an online pharmacy app, a B2B arm that supplies medicines to chemists and hospitals, and the Thyrocare diagnostics chain. It earns mostly from selling products and partly from services such as lab tests.

How does PharmEasy make money?

PharmEasy makes money mainly by selling medicines and health products. In FY26, the sale of products brought in ₹5,670 crore and services, including diagnostics, brought in ₹941.3 crore.

What is the PharmEasy revenue model?

The PharmEasy revenue model is product sales to households, chemists and hospitals plus service income from diagnostics and other services.

How much revenue did PharmEasy make in FY26?

PharmEasy's parent API Holdings earned ₹6,618.5 crore in revenue from operations in FY26, up 12.7% from ₹5,872 crore in FY25.

Is PharmEasy profitable?

No. API Holdings made a net loss of ₹520 crore in FY26, down 67% from ₹1,572 crore in FY25.

Who owns PharmEasy?

PharmEasy is run by API Holdings, an unlisted Mumbai company. Ranjan Pai's family office led its 2023 rights issue.

Who founded PharmEasy?

PharmEasy was founded in 2015 in Mumbai. Its co-founders are Siddharth Shah, Dharmil Sheth, Dhaval Shah, Hardik Dedhia and Harsh Parekh.

What is the PharmEasy valuation?

PharmEasy reached a valuation of $5.6 billion in an October 2021 pre-IPO round. Its 2023 rights issue was priced at about a 90% lower valuation.

How is Thyrocare linked to PharmEasy?

API Holdings agreed to buy 66.1% of Thyrocare in June 2021. After a sale in August 2026, the group holds 51.02%.

How big is PharmEasy's B2B business?

PharmEasy's B2B arm, made up of Ascent and Aknamed, is the largest of the group's businesses by revenue.

How many tests does Thyrocare run?

Thyrocare ran 55.2 million tests across its network in April to June 2026.

Who are PharmEasy's competitors?

PharmEasy competes with Tata 1mg, Apollo 24|7 and Netmeds in online medicines, while Thyrocare competes with Dr Lal PathLabs and Metropolis.

More in Business Models